NEEDHAM, Mass.–(BUSINESS WIRE)–#EnterpriseClientDevices–Faced with an ongoing transition towards alternative devices and challenged budgets, global shipments…
BOSTON–(BUSINESS WIRE)–Hedgehog Lab, a global tech consultancy with a human-centered approach, has named Edward Marshall…
Strengthening the executive leadership team to support the company’s future growth plans LOS GATOS, Calif.–(BUSINESS…
When you mention a knowledge base, many people envision a collection of thin articles, hard…
New York, New York–(Newsfile Corp. – March 13, 2023) – Starfleet Innotech, Inc. (OTC Pink:…
Toronto, Ontario–(Newsfile Corp. – March 13, 2023) – American Aires Inc. (CSE: WIFI) (OTC Pink:…
Cites practice of not providing invoice including principal in loan documents sent to borrowers DALLAS–(BUSINESS…
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (TSX:…
Shiru’s first commercial product, OleoPro™, delivers a 90% saturated fat reduction and improved taste performance…
Shiru’s first commercial product, OleoPro™, delivers a 90% saturated fat reduction and improved taste performance…
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company)…
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company)…
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions”…
NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions”…
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
CAMBRIDGE, Mass., March 13, 2023 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage…
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue…
Recent independent Data Safety Monitoring Board (DSMB) review recommended the INTEGRIS-PSC Phase 2a trial continue…
WARRINGTON, Pa., March 13, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”)…